oNKo-innate

@oNKo_innate

oNKo-Innate is a Melbourne-based discovery-stage company developing therapies that stimulate an innate immune response against cancer.

Vrijeme pridruživanja: listopad 2016.

Tweetovi

Blokirali ste korisnika/cu @oNKo_innate

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @oNKo_innate

  1. 30. sij

    Congratulations to our SAB member Professor on her appointment as CEO of . What a fantastic opportunity to shape medical research in Australia. From all the team congrats and best wishes!

    Poništi
  2. 14. sij

    Our CSO will explain how the role of NK cells in cancer immunity evolves with tumor progression at the American Association of Immunology annual meeting in Hawaii this May for the Society for Natural Immunity (SNI).

    Poništi
  3. 7. sij

    Hhex Is Essential for NK Cell Persistence by Repressing Bcl2l11-Dependent Apoptosis by Wilford Goh, Jacob T…

    Poništi
  4. 5. sij

    All the best for 2020 from the team! Looking forward to updating you all as we advance our NK cell immunotherapies for cancer.

    Poništi
  5. 2. pro 2019.
    Poništi
  6. 1. pro 2019.

    Viral-free primary human NK cell genetic modification. Over a year since this pre-print revealed a novel, efficient approach to generate next generation NK cell therapies

    Poništi
  7. 28. stu 2019.

    Can the tumor microenvironment (TME) skew NK cells into suppressors of tumor immunity? TME does alter NK cell phenotype and function. Preventing this could pave the way for improved immunotherapy response rates

    Poništi
  8. 25. stu 2019.

    What will be the predominant CAR platform of leukemia in 2030

    Poništi
  9. 25. stu 2019.

    Can't argue with that. The biotech sector would welcome some more impactful government support. So few biotech success stories in Oz.......

    Poništi
  10. 17. stu 2019.

    Our CSO is presenting at the annual Allo Cell Therapy Industry meeting in San Diego next March early-bird rego closing in 5 days.

    Poništi
  11. 11. stu 2019.

    oNKo sends a hearty congrats to the team at on the FT500 trial. A huge milestone for the cell therapy field.

    Poništi
  12. 11. stu 2019.

    The reason immunotherapy is such as significant advance is that it is effective in late-stage cancers where all other therapies have failed and previously viewed as terminal cancers. Immunotherapy results is a rapid and durable response.

    Prikaži ovu nit
    Poništi
  13. 11. stu 2019.

    Immunotherapy drug development has increased 91% over the past 2 years from 2030 investigational drugs to 3876 and resulted in a monumental swing in the focus of immunology and cancer researchers.

    Prikaži ovu nit
    Poništi
  14. 18. lis 2019.

    The sun rising over our new home The birthplace of innovation and next generation of NK cell immunotherapies

    Poništi
  15. 16. lis 2019.

    Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response Fascinating review by @CarolynShembrey and Frédéric Hollande

    Poništi
  16. 3. lis 2019.

    was a tour de force! much pre-clinical activity in the CAR NK/allo-NK cell space. very promising phase I data from Katy Razvani on the partial matched CAR19(IL-15) NK cells. Lots of complete responses. 100% safety! CAR NK cells are coming. off-the-shelf & into the clinic!

    Poništi
  17. 3. ruj 2019.

    CAR T cells work better when they are NK cells! Everyone wanting IN on the NK game.

    Poništi
  18. 3. ruj 2019.

    NK cell activity (frequency and function) is required for regression of solid tumors following immune checkpoint blockade (ICB). That's a pretty big deal! Our NK cell therapies should synergize with current market leading ICB approaches to increase response rates.

    Poništi
  19. 3. ruj 2019.

    Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

    Poništi
  20. 3. ruj 2019.

    Congrats Another suppressive TME factor to consider. Great work

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·